TapewireFind a company

person · Reporting owner

Ma Songjiang

Disclosed activity across 1 company

Tapewire entity
79123
SEC CIK
0001985547

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GYRE THERAPEUTICS, INC.GYRE · Entity 5247Director · PresidentMay 27, 2025May 29, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GYRE THERAPEUTICS, INC.

Report date May 27, 2025 · Filed May 29, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Spouse2,806,642 Reported balance After 2025-05-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2025-05-27 · Sale · Disposed 2,000 · Balance 2,806,642

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Common StockSEC Table I · non-derivativeIndirectBy Spouse2,806,084 Reported balance After 2025-05-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2025-05-28 · Sale · Disposed 558 · Balance 2,806,084

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 28, 2025 Filed May 29, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 558 $10.07 $5,619.06
Disclosure

SEC source: 0001140361-25-020754 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,806,084

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 27, 2025 Filed May 29, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.28 $20,560.00
Disclosure

SEC source: 0001140361-25-020754 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,806,642

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 23, 2025 Filed May 27, 2025 20:02 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 182 $10.24 $1,863.68
Disclosure

SEC source: 0001140361-25-020474 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,808,642

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 22, 2025 Filed May 27, 2025 20:02 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.97 $21,940.00
Disclosure

SEC source: 0001140361-25-020474 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,808,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.215 to $11.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 21, 2025 Filed May 22, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.83 $21,660.00
Disclosure

SEC source: 0001140361-25-020156 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,810,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.32 to $11.275. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.25 $22,500.00
Disclosure

SEC source: 0001140361-25-020156 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,812,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.925 to $11.42. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 19, 2025 Filed May 20, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.11 $22,220.00
Disclosure

SEC source: 0001140361-25-019893 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,814,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.02 to $11.215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 16, 2025 Filed May 20, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.31 $22,620.00
Disclosure

SEC source: 0001140361-25-019893 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,816,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.82 to $11.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 15, 2025 Filed May 16, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.68 $21,360.00
Disclosure

SEC source: 0001140361-25-019468 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,818,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.435 to $10.93. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 14, 2025 Filed May 16, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 20 $11.30 $226.00
Disclosure

SEC source: 0001140361-25-019468 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,820,824

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at price of $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 13, 2025 Filed May 14, 2025 20:04 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.37 $22,740.00
Disclosure

SEC source: 0001140361-25-018927 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,820,844

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.16 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 12, 2025 Filed May 14, 2025 20:04 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.56 $21,120.00
Disclosure

SEC source: 0001140361-25-018927 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,822,844

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.885. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 21, 2025 Filed Mar 25, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 174 $10.00 $1,740.00
Disclosure

SEC source: 0001140361-25-010234 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,824,844

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.005. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 20, 2025 Filed Mar 21, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.09 $20,180.00
Disclosure

SEC source: 0001140361-25-009877 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,825,018

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.03 to $10.20. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 19, 2025 Filed Mar 21, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.13 $20,260.00
Disclosure

SEC source: 0001140361-25-009877 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,827,018

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 18, 2025 Filed Mar 19, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 242 $10.24 $2,478.08
Disclosure

SEC source: 0001140361-25-009424 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,829,018

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.09 $24,180.00
Disclosure

SEC source: 0001140361-25-009424 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,829,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.795 to $12.38. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 14, 2025 Filed Mar 17, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.31 $24,620.00
Disclosure

SEC source: 0001140361-25-009017 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,831,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.06 to $12.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.80 $23,600.00
Disclosure

SEC source: 0001140361-25-009017 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,833,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.51 to $11.97. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 12, 2025 Filed Mar 13, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.74 $23,480.00
Disclosure

SEC source: 0001140361-25-008623 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,835,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.135. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 11, 2025 Filed Mar 13, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.40 $22,800.00
Disclosure

SEC source: 0001140361-25-008623 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,837,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.92 to $11.845. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 10, 2025 Filed Mar 11, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.14 $20,280.00
Disclosure

SEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 4

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,839,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.46. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 1,906 $10.13 $19,307.78
Disclosure

SEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 3

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,841,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.365. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 41 $12.14 $497.74
Disclosure

SEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,843,166

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 20:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 53 $13.03 $690.59
Disclosure

SEC source: 0001140361-25-008091 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,843,207

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.80 to $13.47. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 06, 2025 Filed Mar 7, 2025 21:02 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.80 $21,600.00
Disclosure

SEC source: 0001140361-25-007602 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,843,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.63 to $11.17. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 21:02 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.98 $21,960.00
Disclosure

SEC source: 0001140361-25-007602 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,845,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.63 to $11.23. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2025 Filed Mar 5, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $10.86 $21,720.00
Disclosure

SEC source: 0001140361-25-007173 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,847,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.60 to $11.03. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.23 $22,460.00
Disclosure

SEC source: 0001140361-25-007173 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,849,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.95 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.41 $22,820.00
Disclosure

SEC source: 0001140361-25-006738 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,851,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 27, 2025 Filed Mar 3, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.33 $22,660.00
Disclosure

SEC source: 0001140361-25-006738 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,853,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.18 to $11.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 26, 2025 Filed Feb 27, 2025 21:02 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.63 $23,260.00
Disclosure

SEC source: 0001140361-25-006273 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,855,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $11.86. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 21:02 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.37 $22,740.00
Disclosure

SEC source: 0001140361-25-006273 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,857,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.20 to $11.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 24, 2025 Filed Feb 25, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 187 $11.52 $2,154.24
Disclosure

SEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 4

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,859,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F5 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.43 to $11.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 24, 2025 Filed Feb 25, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 1,813 $10.60 $19,217.80
Disclosure

SEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 3

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,859,447

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.41 to $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 182 $12.60 $2,293.20
Disclosure

SEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,861,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.71. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 21, 2025 Filed Feb 25, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 1,818 $11.84 $21,525.12
Disclosure

SEC source: 0001140361-25-005842 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,861,442

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.54 to $12.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.40 $24,800.00
Disclosure

SEC source: 0001140361-25-005420 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,863,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.15 to $12.61. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.29 $24,580.00
Disclosure

SEC source: 0001140361-25-005420 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,865,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.1 to $12.62. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 18, 2025 Filed Feb 19, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.49 $24,980.00
Disclosure

SEC source: 0001140361-25-005113 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,867,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.26 to $12.78. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.94 $23,880.00
Disclosure

SEC source: 0001140361-25-005113 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,869,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.78 to $12.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 13, 2025 Filed Feb 14, 2025 21:00 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.69 $23,380.00
Disclosure

SEC source: 0001140361-25-004744 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,871,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.59 to $11.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 21:00 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.49 $22,980.00
Disclosure

SEC source: 0001140361-25-004744 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,873,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.25 to $11.645. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 11, 2025 Filed Feb 13, 2025 01:45 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 1,878 $11.52 $21,634.56
Disclosure

SEC source: 0001140361-25-004126 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,875,260

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.45 to $11.61. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 10, 2025 Filed Feb 13, 2025 01:45 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.90 $23,800.00
Disclosure

SEC source: 0001140361-25-004126 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,877,138

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.72 to $12.12. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 07, 2025 Filed Feb 11, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.16 $24,320.00
Disclosure

SEC source: 0001140361-25-003831 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,879,158

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.01 to $12.475. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 06, 2025 Filed Feb 11, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $12.85 $25,700.00
Disclosure

SEC source: 0001140361-25-003831 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,881,138

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.70 to $13.05. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 05, 2025 Filed Feb 6, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 20 $12.84 $256.80
Disclosure

SEC source: 0001140361-25-003426 · form4.xml · nonDerivative · entry 3

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,883,138

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.835 to $12.84. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 05, 2025 Filed Feb 6, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 1,980 $12.39 $24,532.20
Disclosure

SEC source: 0001140361-25-003426 · form4.xml · nonDerivative · entry 2

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,883,158

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.82 to $12.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:01 UTC GYRE THERAPEUTICS, INC. GYRE · Entity 5247 SaleCommon Stock 2,000 $11.62 $23,240.00
Disclosure

SEC source: 0001140361-25-003426 · form4.xml · nonDerivative · entry 1

Ma Songjiang · CIK 0001985547 · Director · President

10b5-1 filing: Plan reported

Ownership: Indirect · By Spouse

Disclosed balance after: 2,885,138

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.33 to $11.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.